The aim of this study is to evaluate the monitoring of moderate diabetic retinopathy by tele-expertise


Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 13, 2022

Detailed Description

This study compares 2 strategies of monitoring of moderate diabetic retinopathy (RD).After a consultation with an orthoptist for measurement of visual acuity, measurement of ocular tone by pulsed air tonometer, retinography pictures (9 photographs: one of the posterior pole and 8 of the retinal periphery) and Optical Coherence Tomography (OCT), results are evaluated on-site by an ophthalmologist and then sent through a secure medical online application to an ophthalmologist expert in RD for assessment. Each patient is his own control.


  • Other: moderate diabetic retinopathy follow-up by tele-expertise
    • Consultation by an orthoptist to measure visual acuity, eye tone by pulsed air tonometer, and retinography images after pupillary dilatation (9 photographs: one of the posterior pole and 8 of the peripheral retina) and optical coherence tomography (OCT). The results are immediately evaluated on site by an ophthalmologist. The results are sent through a secure online medical application to a diabetic retinopathy specialist ophthalmologist for evaluation.

Clinical Trial Outcome Measures

Primary Measures

  • classification of diabetic retinopathy (DR)
    • Time Frame: 1 month
    • DR is classified in 3 stages : moderate non proliferative DR, severe non proliferative DR, and proliferative DR

Secondary Measures

  • classification of macular edema
    • Time Frame: 1 month
    • macular edema (ME) is classified in 4 stages : no ME , mild ME, moderate ME, severe ME
  • follow-up strategy
    • Time Frame: 1 month
    • follow-up strategy can take to ways : no treatment required and continuation of the monitoring/ complementary exam or treatment required
  • medical time necessary for examination and analyse
    • Time Frame: 1 month
    • time necessary for direct examination and analyse by ophthalmologist on-site and time necessary for remote analyse are measured

Participating in This Clinical Trial

Inclusion Criteria

  • patient with complicated diabetes mellitus with moderate retinopathy Exclusion Criteria:

  • Patient deprived of liberty by judicial or administrative decision – Person subject to a legal protection measure – Patient already involved in another clinical trial protocol

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Sud Francilien
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Alfred Penfornis, Principal Investigator, Centre Hospitalier Sud Francilien
  • Overall Contact(s)
    • François-Xavier Laborne, MD, +33169139597,


Schulze-Döbold C, Erginay A, Robert N, Chabouis A, Massin P. Ophdiat(®): five-year experience of a telemedical screening programme for diabetic retinopathy in Paris and the surrounding area. Diabetes Metab. 2012 Nov;38(5):450-7. doi: 10.1016/j.diabet.2012.05.003. Epub 2012 Jul 4.

Chabouis A, Berdugo M, Meas T, Erginay A, Laloi-Michelin M, Jouis V, Guillausseau PJ, M'bemba J, Chaine G, Slama G, Cohen R, Reach G, Marre M, Chanson P, Vicaut E, Massin P. Benefits of Ophdiat, a telemedical network to screen for diabetic retinopathy: a retrospective study in five reference hospital centres. Diabetes Metab. 2009 Jun;35(3):228-32. doi: 10.1016/j.diabet.2008.12.001. Epub 2009 Apr 5.

Erginay A, Chabouis A, Viens-Bitker C, Robert N, Lecleire-Collet A, Massin P. OPHDIAT: quality-assurance programme plan and performance of the network. Diabetes Metab. 2008 Jun;34(3):235-42. doi: 10.1016/j.diabet.2008.01.004.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.